Preview

Rational Pharmacotherapy in Cardiology

Advanced search

IMIDAZOLINE RECEPTOR AGONISTS: DO WE KNOW EVERYTHING ABOUT THEIR CAPABILITIES?

https://doi.org/10.20996/1819-6446-2012-8-2-233-236

Full Text:

Abstract

The role of selective I1 imidazoline receptor agonists and moxonidine in particular , in modern antihypertensive therapy is discussed. Moxonidine advantages, namely positive effects on insulin resistance, endothelial dysfunction, lipid profile, and plasma fibrinolytic activity are considered.

About the Authors

D. V. Nebieridze
State Research Center for Preventive Medicine
Russian Federation


T. V. Kamyshova
State Research Center for Preventive Medicine
Russian Federation


References

1. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J 1998; 19 (Suppl F): F14–18.

2. Bousquet P , Feldman. J, Schwartz J. Central cardiovascular effects of alpha-adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984; 230:232–236.

3. Parini A. Du recepteur alpha-2 adrenergique au recepteur imidazolinique - guanidinique: un concept en evolution. Lettre du Pharmacol 1989; 6 (Suppi): 3–5

4. van Zwieten PA. Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: mox-onidine and rilmenidine. J Hypertens 1997;15(2):117–25.

5. Nebieridze D.V., Britov A.N., Aparina T.V. et al. Moxonidine and others - the modern drug of choice for hypertension and metabolic disorders. Kardiologiia 1999; 39(1): 43–47. Russian (Небиеридзе Д.В., Бритов А.Н., Апарина Т .В. и др. Моксонидин — современный препарат выбора при артериальной гипертонии и метаболических нарушениях. Кардиология 1999; 39(1): 43–47).

6. Chazova I.E., Almazov V.A., Shlyakhto E.V. Moxonidine improves glycemic control in patients with arterial hypertension and excess body weight in comparison with metformin: the ALMAZ study. Obzory Klinicheskoy Kardiologii 2007; (9): 36–47. Russian (Чазова И.Е., Алмазов В.А., Шляхто Е.В. Моксонидин улучшает гликемический контроль у пациентов с артериальной гипертонией и избы- точной массой тела в сравнении с метформином: исследование АЛМАЗ. Обзоры Клинической Кардиологии 2007; (9): 36–47).

7. Julius S, Gudbradson T, Jamerson K et al. The hemodynamic link between insulin resistance and hypertension. J Hypertension. 1991; 9; 983–986.

8. Haenni A, Lithell HO. Moxonidin improves insulin sensitivity in insulin-resistent hypertensives. J Hypertens 1999; 17 (Suppl 3): S29–S35

9. Shilov A.M., Avshalumov A.Sh., Markovskiy V.B. et al. Pathophysiologic features of hypertension in obesity: diagnosis and treatment guidelines. Lechashchiy Vrach 2009; (2): 1–4. Russian (Шилов А.М., Авшалумов А.Ш., Марковский В.Б. и др. Патофизиологические особенности артериальной гипертонии при ожирении: диагностика и принципы лечения. Лечащий врач 2009; (2): 1–4).

10. Shilov A.M., Avshalumov A.Sh., Osiya A., Gryaznov D. Arterial hypertension, abdominal obesity , impaired glucose tolerance. Vrach 2010; (9): 61–65. Russian (Шилов А.М., Авшалумов А.Ш., Осия А., Г рязнов Д. Артериальная гипертензия, абдоминальное ожирение, нарушение толерантности к глюкозе. Врач 2010; (9): 61– 65).

11. Krespi PG, Makris TK, Hatzizacharias AN, et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor — 1 levels in patients with essential hypertension. J Cardiovasc Drugs and Therapy 1998; 12: 463–467.

12. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105–87.

13. National guidelines for diagnosis and treatment of hypertension. Kardiovaskulyarnaya Terapiya i Profilaktika 2008; 7(6) suppl 2: 1–36. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Кардиоваскулярная Терапия и Профилактика 2008; 7(6) Приложение 2: 1–36).


For citation:


Nebieridze D.V., Kamyshova T.V. IMIDAZOLINE RECEPTOR AGONISTS: DO WE KNOW EVERYTHING ABOUT THEIR CAPABILITIES? Rational Pharmacotherapy in Cardiology. 2012;8(2):233-236. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-2-233-236

Views: 757


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)